Catalyst Pharmaceuticals (CPRX) Tops Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
KELYA, ROX, KEEL, More
Financial Fact:
General and administrative: 1.42M
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q1 EPS of $0.41, $0.09 better than the analyst estimate of $0.32. Revenue for the quarter came in at $85.4 million versus the consensus estimate of $81.62 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2023 revenue of $195-205 million, versus the consensus of $165.8 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loar Holdings Inc. (LOAR) Reports Q3 EPS of $0.39 ; Offers Guidance
- Vericel (VCEL) Tops Q3 EPS by 21c; Offers Guidance
- Kelly Services (KELYA) Misses Q3 EPS by 5c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
